EA
ENZ

Emerald Advisers’s Enzo Biochem, Inc. ENZ Stock Holding History

Emerald Advisers’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,860
Closed -$10K – 417
2014
Q2 		$10K Buy
+1,860
New +$8.04K ﹤0.01% 416

Other funds holding ENZ

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPIM
Columbia Partners Investment Management Alexandria, Virginia $257M AUM 8.17% 1-Year Est. Return

Emerald Advisers's ENZ Position: Q3 2014 in Review

Emerald Advisers sold out of Enzo Biochem, Inc. (ENZ) in Q3 2014, closing a stake of 1,860 shares — an estimated $10K sold.

Emerald Advisers first reported a position in ENZ in Q2 2014 and held it in 1 quarter. The position peaked at $10K in Q2 2014. 92 funds tracked by Wall St. Rank hold ENZ as of Q3 2014.

  • Emerald Advisers reported no remaining Enzo Biochem, Inc. position as of Q3 2014 after selling out during the quarter.
  • Emerald Advisers sold 1,860 Enzo Biochem, Inc. shares in Q3 2014, an estimated $10K.
  • Emerald Advisers first reported a position in Enzo Biochem, Inc. in Q2 2014 and held it in 1 quarter.
  • Emerald Advisers's Enzo Biochem, Inc. position peaked at $10K in Q2 2014.
  • 92 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2014.

Based on Emerald Advisers's 13F filing for Q3 2014, filed 28 Oct 2014.